Elizabeth-AnnWeeks Ph.D. (EA)

Associate

Atlanta + 1.404.581.8821

Dr. Elizabeth-Ann (EA) Weeks focuses her practice on patent portfolio counseling and intellectual property transactions in the chemical, biotechnical, and pharmaceutical sciences.

EA works with clients on the development and management of worldwide patent portfolios. She advises clients on early- to late-stage life-cycle strategies and regulatory extension opportunities. She has managed patent portfolios and procured patents in a broad range of technologies in the life sciences and chemical arts.

EA also advises clients on a variety of intellectual property transactions, including licensing and due diligence matters. She regularly drafts and reviews license agreements and performs competitive intelligence, patentability, and freedom-to-operate analyses. In addition, she has experience in patent litigation (including Hatch-Waxman litigation) and post-grant proceedings at the U.S. Patent and Trademark Office.

EA's doctoral research at Georgia Tech spanned several areas of chemistry, including organic chemistry, biochemistry, polymer chemistry, and physical chemistry. Her primary work focused on the photochemistry and photophysics of excited-state proton transfer in various small molecules that was applied to a number of technologies, including drug delivery systems, proton pumps in biological systems, and fuel cell applications.

After obtaining her Ph.D. in 2012, EA practiced as a patent agent at a global law firm while attending law school.

Experience

  • PGT Innovations to acquire 75% ownership stake in Eco Window Systems for $108 millionJones Day is advising PGT Innovations, Inc. in its $108 million acquisition of a 75% ownership stake in Eco Window Systems and its related companies, leading manufacturers and installers of aluminum, impact-resistant windows and doors serving the South Florida region.
  • J.F. Lehman & Company acquires CTS EnginesJones Day advised J.F. Lehman & Company, a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental sectors, in the acquisition of CTS Engines, LLC and CTS Testing, LLC.
  • Bally's to acquire Bet.Works for $125 million and announces strategic partnership with Sinclair BroadcastJones Day is advising Bally's Corporation in its $125 million acquisition of Bet.Works, a U.S. based sports betting platform provider to operators in New Jersey, Iowa, Indiana, and Colorado, and a long-term strategic partnership with Sinclair Broadcast Group, Inc., pursuant to which 21 FOX RSN brands will be rebranded using the Bally’s name and Bally’s will integrate content into the 190 television stations that Sinclair owns, operates, or provides services to across 88 markets and sports networks.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day is advising Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Twin River Worldwide Holdings acquires iconic Bally's brand from Caesars EntertainmentJones Day advised Twin River Worldwide Holdings, Inc. in the acquisition of the iconic Bally's brand previously owned by Caesars Entertainment, Inc.
  • Playboy to become public company by combining with Mountain Crest Acquisition Corp.Jones Day is advising Playboy Enterprises, Inc. in its definitive merger agreement with Mountain Crest Acquisition Corp. (Nasdaq: MCAC) ("Mountain Crest"), a publicly-traded special purpose acquisition corporation (SPAC), whereby Playboy shareholders will be entitled to receive shares of common stock in Mountain Crest, and Mountain Crest will assume outstanding Playboy debt, for a total purchase price valued at approximately $381 million.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Hard Rock International acquires JACK Cincinnati Casino and Turfway Park for $745 millionJones Day advised Hard Rock International on the acquisition of JACK Cincinnati Casino, located in downtown Cincinnati, Ohio, together with VICI Properties, Inc., and Turfway Park, located in Florence, Kentucky, for an aggregate purchase price of approximately $745 million in cash.
  • AbbVie acquires MavupharmaJones Day advised AbbVie Inc. in its acquisition of Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
  • Royalty Pharma acquires EMGALITY® royalty from Arteaus Therapeutics for $260 millionJones Day advised Royalty Pharma, the industry leader in acquiring pharmaceutical royalties, in its $260 million acquisition of the royalty interest held by Arteaus Therapeutics, LLC on future global net sales of Eli Lilly and Company’s EMGALITY® (galcanezumab), an anti-CGRP antibody for the prevention of migraine.
  • Rain Therapeutics expands patent portfolio related to clinical stage cancer therapiesJones Day advised Rain Therapeutics Inc. in connection with global patent portfolio development related to a hypoxia-activated prodrug of a potent pan-HER inhibitor, Tarloxotinib (Tarlox), for the treatment of non-small cell lung cancer in patients with EGFR and HER exon 20 insertion mutations.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.